For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development expenses | 9,813 | |||
| General and administrative expenses | 6,277 | |||
| Total operating expenses | 16,090 | |||
| Loss from operations | -16,090 | |||
| Other (income) expense | 26 | |||
| Change in fair value of derivative liability | -3,267 | |||
| Finance expense, net | -57 | |||
| Total other income | -3,298 | |||
| Net loss | -19,388 | |||
| Foreign currency translation adjustment | 49 | |||
| Comprehensive loss | -19,339 | |||
| Basic EPS | 31.22 | |||
| Diluted EPS | 31.22 | |||
| Basic Average Shares | 621,094 | |||
| Diluted Average Shares | 621,094 | |||
Glucotrack, Inc. (GCTK)
Glucotrack, Inc. (GCTK)